{"id":"placebo-for-saxagliptin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2103745","moleculeType":"Small molecule","molecularWeight":"333.43"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo for Saxagliptin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:59:09.723894+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:59:21.532493+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo for Saxagliptin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:59:22.377882+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103745/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:59:23.426996+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In the context of a Saxagliptin trial, placebo serves as the comparator arm to demonstrate that observed benefits are due to Saxagliptin's DPP-4 inhibition, not expectation alone.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:00.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:59:25.215545+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials for type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02597101","phase":"PHASE2","title":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes","status":"COMPLETED","sponsor":"Nick Giannoukakis, PhD","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":14},{"nctId":"NCT02965443","phase":"PHASE4","title":"Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2018-02-02","conditions":"Type 2 Diabetes","enrollment":4},{"nctId":"NCT01548651","phase":"PHASE4","title":"Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2012-02","conditions":"Impaired Glucose Tolerance","enrollment":8},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02024477","phase":"PHASE4","title":"Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients","status":"COMPLETED","sponsor":"George Washington University","startDate":"2013-11","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT02681094","phase":"PHASE3","title":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-02-26","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":905},{"nctId":"NCT02104739","phase":"PHASE4","title":"Effects of Antidiabetic Medications on the Postprandial State in Prediabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-04","conditions":"Prediabetes, Obesity","enrollment":21},{"nctId":"NCT02304081","phase":"PHASE4","title":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function","status":"COMPLETED","sponsor":"Prof. Dr. Thomas Forst","startDate":"2015-01","conditions":"Type2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT02742233","phase":"PHASE4","title":"Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers","status":"UNKNOWN","sponsor":"Long Min,MD","startDate":"2015-11","conditions":"Diabetic Foot Ulcer","enrollment":60},{"nctId":"NCT01582308","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-21","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT00857558","phase":"PHASE2","title":"A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-01","conditions":"Diabetes, Type 2","enrollment":350},{"nctId":"NCT01192659","phase":"","title":"Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":16492},{"nctId":"NCT00757588","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-11","conditions":"Type 2 Diabetes","enrollment":455},{"nctId":"NCT01765270","phase":"PHASE4","title":"Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery","status":"TERMINATED","sponsor":"Duke University","startDate":"2013-03","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":12},{"nctId":"NCT00374907","phase":"PHASE3","title":"A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Type 2 Diabetes","enrollment":156},{"nctId":"NCT00121667","phase":"PHASE3","title":"Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-08","conditions":"Diabetes Mellitus, Type 2","enrollment":1462},{"nctId":"NCT02239458","phase":"NA","title":"DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis","status":"UNKNOWN","sponsor":"Ram Weiss","startDate":"2015-06","conditions":"Cystic Fibrosis","enrollment":60},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT01521312","phase":"PHASE2","title":"ACute and Chronic Effects of Saxagliptin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-09","conditions":"Impaired Glucose Tolerance","enrollment":24},{"nctId":"NCT01552018","phase":"PHASE4","title":"Saxagliptin and Atherosclerosis","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2012-03","conditions":"Coronary Artery Disease, Diabetes Mellitus Type 2","enrollment":12},{"nctId":"NCT01319357","phase":"PHASE3","title":"Effects of Saxagliptin on Endothelial Function","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-10","conditions":"Diabetes Mellitus Type 2","enrollment":52},{"nctId":"NCT01128153","phase":"PHASE3","title":"Saxagliptin Triple Oral Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":257},{"nctId":"NCT00661362","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":570},{"nctId":"NCT00918879","phase":"PHASE3","title":"Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes","enrollment":213},{"nctId":"NCT00698932","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":568}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2103745"},"_approvalHistory":[],"publicationCount":195,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insulin: intermediate-acting or basal or premixed ( include short- or rapid-acting insulin as one component). ≥20 unit/day, ≤150 units/day","Metformin: Glucophage, 500-2500mg/day"],"phase":"marketed","status":"active","brandName":"Placebo for Saxagliptin","genericName":"Placebo for Saxagliptin","companyName":"Prof. Dr. Thomas Forst","companyId":"prof-dr-thomas-forst","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in clinical trials for type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:59:25.215545+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}